BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 12679453)

  • 1. The effect of cessation of growth hormone (GH) therapy on bone mineral accretion in GH-deficient adolescents at the completion of linear growth.
    Drake WM; Carroll PV; Maher KT; Metcalfe KA; Camacho-Hübner C; Shaw NJ; Dunger DB; Cheetham TD; Savage MO; Monson JP
    J Clin Endocrinol Metab; 2003 Apr; 88(4):1658-63. PubMed ID: 12679453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency.
    Janssen YJ; Hamdy NA; Frölich M; Roelfsema F
    J Clin Endocrinol Metab; 1998 Jun; 83(6):2143-8. PubMed ID: 9626153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe GH deficiency at completion of linear growth.
    Carroll PV; Drake WM; Maher KT; Metcalfe K; Shaw NJ; Dunger DB; Cheetham TD; Camacho-Hübner C; Savage MO; Monson JP
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3890-5. PubMed ID: 15292323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of growth hormone therapy and puberty on bone and body composition in children with idiopathic short stature and growth hormone deficiency.
    Högler W; Briody J; Moore B; Lu PW; Cowell CT
    Bone; 2005 Nov; 37(5):642-50. PubMed ID: 16139578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency.
    Conway GS; Szarras-Czapnik M; Racz K; Keller A; Chanson P; Tauber M; Zacharin M;
    Eur J Endocrinol; 2009 Jun; 160(6):899-907. PubMed ID: 19324976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary pyridinium collagen cross-links predict growth performance in children with idiopathic short stature and with growth hormone (GH) deficiency treated with GH. Skeletal metabolism during GH treatment.
    Spagnoli A; Branca F; Spadoni GL; Cianfarani S; Pasquino AM; Argirò G; Vitale S; Robins SP; Boscherini B
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3589-93. PubMed ID: 8855806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of growth hormone (GH) treatment on bone in postpubertal GH-deficient patients: a 2-year randomized, controlled, dose-ranging study.
    Shalet SM; Shavrikova E; Cromer M; Child CJ; Keller E; Zapletalová J; Moshang T; Blum WF; Chipman JJ; Quigley CA; Attanasio AF
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4124-9. PubMed ID: 12970274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy.
    Thorén M; Hilding A; Brismar T; Magnusson P; Degerblad M; Larsson L; Sääf M; Baylink DJ; Mohan S
    J Bone Miner Res; 1998 May; 13(5):891-9. PubMed ID: 9610754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal changes of lumbar bone mineral density (BMD) in patients with GH deficiency after discontinuation of treatment at final height; timing and peak values for lumbar BMD.
    Baroncelli GI; Bertelloni S; Sodini F; Saggese G
    Clin Endocrinol (Oxf); 2004 Feb; 60(2):175-84. PubMed ID: 14725678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the growth hormone replacement on bone status in growth hormone deficient adults.
    Kužma M; Kužmová Z; Zelinková Z; Killinger Z; Vaňuga P; Lazurová I; Tomková S; Payer J
    Growth Horm IGF Res; 2014 Feb; 24(1):22-8. PubMed ID: 24382377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of growth hormone on accretion of bone mass.
    Monson JP; Drake WM; Carroll PV; Weaver JU; Rodriguez-Arnao J; Savage MO
    Horm Res; 2002; 58 Suppl 1():52-6. PubMed ID: 12373015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group.
    Mauras N; Attie KM; Reiter EO; Saenger P; Baptista J
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3653-60. PubMed ID: 11061518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
    Fernholm R; Bramnert M; Hägg E; Hilding A; Baylink DJ; Mohan S; Thorén M
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4104-12. PubMed ID: 11095440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skeletal consequences of discontinuation of growth hormone at final height.
    Drake WM; Carroll PV; Savage MO; Monson JP
    J Pediatr Endocrinol Metab; 2002 Dec; 15 Suppl 5():1351-4. PubMed ID: 12510990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients.
    Longobardi S; Di Rella F; Pivonello R; Di Somma C; Klain M; Maurelli L; Scarpa R; Colao A; Merola B; Lombardi G
    J Endocrinol Invest; 1999 May; 22(5):333-9. PubMed ID: 10401706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency.
    Biller BM; Sesmilo G; Baum HB; Hayden D; Schoenfeld D; Klibanski A
    J Clin Endocrinol Metab; 2000 Mar; 85(3):970-6. PubMed ID: 10720025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults.
    Cuneo RC; Judd S; Wallace JD; Perry-Keene D; Burger H; Lim-Tio S; Strauss B; Stockigt J; Topliss D; Alford F; Hew L; Bode H; Conway A; Handelsman D; Dunn S; Boyages S; Cheung NW; Hurley D
    J Clin Endocrinol Metab; 1998 Jan; 83(1):107-16. PubMed ID: 9435425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in bone mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiency.
    Boot AM; Engels MA; Boerma GJ; Krenning EP; De Muinck Keizer-Schrama SM
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2423-8. PubMed ID: 9253311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism.
    Colao A; Di Somma C; Pivonello R; Loche S; Aimaretti G; Cerbone G; Faggiano A; Corneli G; Ghigo E; Lombardi G
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1919-24. PubMed ID: 10372687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of idiopathic childhood-onset growth hormone deficiency (GHD) on bone mass in subjects without adult GHD.
    Lange M; Müller J; Svendsen OL; Kastrup KW; Juul A; Feldt-Rasmussen U
    Clin Endocrinol (Oxf); 2005 Jan; 62(1):18-23. PubMed ID: 15638865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.